<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32022482</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>A juvenile ALS-like phenotype dramatically improved after high-dose riboflavin treatment.</ArticleTitle><Pagination><StartPage>250</StartPage><EndPage>253</EndPage><MedlinePgn>250-253</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.50977</ELocationID><Abstract><AbstractText>Riboflavin transporter deficiency (RTD) was recently characterized as a cause of genetic recessive childhood-onset motor neuron disease (MND) with hearing loss, formerly described as Brown-Vialetto-Van-Lear syndrome. We describe a 18-year-old woman with probable RTD mimicking juvenile Amyotrophic Lateral Sclerosis (ALS) who presented with an inaugural respiratory failure and moderate distal four limbs weakness. Only one heterozygous SLC52A3 mutation was detected, but presence of a sub-clinical auditory neuropathy and dramatic improvement under high dose riboflavin argued for a RTD. As RTD probably has a larger phenotypic spectrum than expected, a high dose riboflavin trial should be discussed in young-onset MND.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carreau</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7000-9367</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenglet</LastName><ForeName>Timoth&#xe9;e</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurophysiology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosnier</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Otology, Auditory Implants and Skull Base Surgery, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahlou</LastName><ForeName>Ghizlene</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Otology, Auditory Implants and Skull Base Surgery, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fargeot</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurophysiology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demeret</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salachas</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veauville-Merlli&#xe9;</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Inborn Errors of Metabolism and Neonatal Screening, Center of Biology and Pathology Est, CHU Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acquaviva</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Inborn Errors of Metabolism and Neonatal Screening, Center of Biology and Pathology Est, CHU Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadjar</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re (AP-HP), 47-83 Boulevard de l'H&#xf4;pital, 75013, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>12001-76-2</RegistryNumber><NameOfSubstance UI="D014803">Vitamin B Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>TLM2976OFR</RegistryNumber><NameOfSubstance UI="D012256">Riboflavin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C537111">Brown-Vialetto-Van Laere syndrome</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010244" MajorTopicYN="N">Bulbar Palsy, Progressive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006319" MajorTopicYN="N">Hearing Loss, Sensorineural</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012256" MajorTopicYN="N">Riboflavin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014803" MajorTopicYN="N">Vitamin B Complex</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>CC, TL, IM, GL, GF, NW, SD, FS, AV, and CA have nothing to disclose. YN received speech honoraria from Actelion and Orphan Europe; and received travel funding from Actelion, Shire and Genzyme.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32022482</ArticleId><ArticleId IdType="pmc">PMC7034506</ArticleId><ArticleId IdType="doi">10.1002/acn3.50977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manole A, Jaunmuktane Z, Hargreaves I, et al. Clinical, pathological and functional characterization of riboflavin&#x2010;responsive neuropathy. Brain J Neurol 2017;140:2820&#x2013;2837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808726</ArticleId><ArticleId IdType="pubmed">29053833</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger B, Bosch AM. Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience. J Inherit Metab Dis 2016;39:559&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920840</ArticleId><ArticleId IdType="pubmed">26973221</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch AM, Abeling NGGM, Ijlst L, et al. Brown&#x2010;Vialetto&#x2010;Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J Inherit Metab Dis 2011;34:159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026695</ArticleId><ArticleId IdType="pubmed">21110228</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand G, Hasan N, Jayapal S, et al. Early use of high&#x2010;dose riboflavin in a case of Brown&#x2010;Vialetto&#x2010;Van Laere syndrome. Dev Med Child Neurol 2012;54:187&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">22098162</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan B, Bosch AM, Houlden H. An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency. J Inher Metab Dis 2019;42:598&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">30793323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosgrove J, Datta S, Busby M. Adult onset Brown&#x2010;Vialetto&#x2010;Van Laere syndrome with opsoclonus and a novel heterozygous mutation: a case report. Clin Neurol Neurosurg 2015;128:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25462087</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison T, Roncero I, Forsyth R, et al. Brown&#x2010;Vialetto&#x2010;Van Laere syndrome as a mimic of neuroimmune disorders: 3 cases from the clinic and review of the literature. J Child Neurol 2017;32:528&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">28116953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccolella M, Catteruccia M, Benedetti S, et al. Brown&#x2010;Vialetto&#x2010;van Laere and Fazio&#x2010;Londe overlap syndromes: a clinical, biochemical and genetic study. Neuromuscul Disord 2012;22:1075&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">22824638</ArticleId></ArticleIdList></Reference><Reference><Citation>Dezfouli MA, Yadegari S, Nafissi S, Elahi E. Four novel C20orf54 mutations identified in Brown&#x2010;Vialetto&#x2010;Van Laere syndrome patients. J Hum Genet 2012;57:613&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">22718020</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandran R, Alexander M, Naina P, Balraj A. Auditory neuropathy spectrum disorder with Brown&#x2010;Vialetto&#x2010;Van Laere syndrome: challenges in hearing rehabilitation. J. Laryngol Otol 2015;129:504&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">25994385</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>